Journal of Pharmaceutical Investigation

  • 제39권3호
  • /
  • Pages.177-183
  • /
  • 2009
  • /
  • 2093-5552(pISSN)
  • /
  • 2093-6214(eISSN)
한국약제학회 (The Korean Society of Pharmaceutical Sciences and Technology)
권호 표지
DOI QR코드

DOI QR Code

토끼 혈장 중 피록시캄의 HPLC 분석 및 패취제 투여 후 경피흡수

HPLC Analysis of Piroxicam in the Rabbit Plasma and its Bioavailability after the Transdermal Administration of Patches

  • 신대환 (충북대학교 약학대학, 충북BIT연구중심대학육성사업단) ;
  • 박승혁 (충북대학교 약학대학, 충북BIT연구중심대학육성사업단) ;
  • 이경복 (충북대학교 약학대학, 충북BIT연구중심대학육성사업단) ;
  • 이종길 (충북대학교 약학대학, 충북BIT연구중심대학육성사업단) ;
  • 정연복 (충북대학교 약학대학, 충북BIT연구중심대학육성사업단)
  • 발행 : 2009.06.20
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

A rapid and sensitive reversed-phase high performance liquid chromatography (HPLC) method was developed for the determination of piroxicam in the rabbit plasma. After a treatment of plasma sample by liquid-liquid extraction, the drug was analyzed on an HPLC system with ultraviolet detection at 330 nm. HPLC was carried out using reversed-phase isocratic elution with a C18 column, a mobile phase of a mixture of acetonitril, doubly deionized water and acetic acid 43.74:56.00:0.26 v/v%) at a flow rate of 1.1 mL/min. The chromatograms showed good resolution and sensitivity and no interference of plasma. The calibration curve for the drug in plasma sample was linear over the concentration range of 0.01-2.0 ${\mu}$g/mL. The intra- and inter-day assay accuracies of this method ranged from 86.82% to 108.33% of normal values and the precision did not exceed 13% of relative standard deviation. The plasma concentration of piroxicam decreased to below the quantifiable limit at 12 hr after the i.v. bolus administration to rabbits following dose of 0.375 mg/kg yielding a apparen t plasma half life of 1.38 hr. The transdermal route prolongs plasma levels of piroxicam. The bioavailability, calculated from the dose-adjusted ratio of the $AUC_{transdermal}$ to the $AUC_{i.v.}$, was 7.44%. The plasma concentration of piroxicam was detected by 48 hr after the transdermal administration of patch at a dose of 32 mg/kg. This method was suitable for cutaneous absorption studies of piroxicam in the rabbit after transdermal administration of different types of dosages of the drug.

키워드

참고문헌

  1. M.M. Meshali, H.M. Abdel-Aleem, F.M. Sakr, S. Nazzal and Y. El-Malah, In vitro phonophoresis: effect of ultrasound intensity and mode at high frequency on NSAIDs transport across cellulose and rabbit skin membranes, Pharmazie., 63, 49-53 (2008)
  2. J. Czares-Delgadillo, A. Naik, Y.N. Kalia, D. Quintanar-Guerrero and A. Ganem-Quintanar, Skin permeation enhancement by sucrose esters: a pH-dependent phenomenon, Int. J. Pharm., 297, 204-212 (2005) https://doi.org/10.1016/j.ijpharm.2005.03.020
  3. G.P. Agrawal, M. Juneja, S. Agrawal, S.K. Jain and S.S. Pancholi,, Preparation and characterization of reverse micelle based organogels of piroxicam, Pharmazie., 59, 191-193 (2004)
  4. A. Doliwa, S. Santoyo and P. Ygartua, Transdermal lontophoresis and skin retention of piroxicam from gels containing piroxicam: hydroxypropyl-beta-cyclodextrin complexes, Drug Dev. Ind. Pharm., 27, 751-758 (2001) https://doi.org/10.1081/DDC-100107238
  5. E. Beetge, J. du Plessis, D.G. Mller, C. Goosen and F.J. van Rensburg, The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption, Int. J. Pharm., 193, 261-264 (2000) https://doi.org/10.1016/S0378-5173(99)00340-3
  6. Y. Yuan, X. Chen and D. Zhong, Determination of meloxicam in human plasma by liquid chromatographytandem mass spectrometry following transdermal administration, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 852, 650-654 (2007) https://doi.org/10.1016/j.jchromb.2007.01.036
  7. T. Penzes, G. Blazso, Z. Aigner, G. Falkay and I. Eros, Topical absorption of piroxicam from organogels-in vitro and in vivo correlations, Int. J. Pharm., 298, 47-54 (2005) https://doi.org/10.1016/j.ijpharm.2005.03.013
  8. A. Doliwa, S. Santoyo, M.A. Campanero and P. Ygartua, Sensitive LC determination of piroxicam after in vitro transdermal permeation studies, J. Pharm. Biomed. Anal., 26, 531-537 (2001) https://doi.org/10.1016/S0731-7085(01)00455-1
  9. I. Csoka, E. Csanyi, G. Zapantis, E. Nagy, A. Fehr-Kiss, G. Horvth, G. Blazs and I. Eros, In vitro and in vivo percutaneous absorption of topical dosage forms: case studies, Int. J. Pharm., 291, 11-19 (2005) https://doi.org/10.1016/j.ijpharm.2004.07.038
  10. S.N. Murthy, Y.L. Zhao, A. Sen and S.W. Hui, Cyclodextrin enhanced transdermal delivery of piroxicam and carboxyfluorescein by electroporation, J. Control. Release., 99, 393-402 (2004) https://doi.org/10.1016/j.jconrel.2004.07.026
  11. C. Curdy, Y.N. Kalia, A. Naik and R.H. Guy, Piroxicam delivery into human stratum corneum in vivo: iontophoresis versus passive diffusion, J. Control. Release., 76, 73-79 (2001) https://doi.org/10.1016/S0168-3659(01)00418-7
  12. E. Larrucea, A. Arellano, S. Santoyo and P. Ygartua, Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin, Eur. J. Pharm. Biopharm., 52, 113-119 (2001) https://doi.org/10.1016/S0939-6411(01)00158-8
  13. J.A. Cordero, M. Camacho, R. Obach, J. Domenech and L. Vila, In vitro based index of topical anti-inflammatory activity to compare a series of NSAIDs, Eur. J. Pharm. Biopharm., 51, 135-142 (2001) https://doi.org/10.1016/S0939-6411(00)00149-1
  14. C. Rasetti-Escargueil and V. Grange, Pharmacokinetic profiles of two tablet formulations of piroxicam, Int. J. Pharm., 295, 129-134 (2005) https://doi.org/10.1016/j.ijpharm.2005.02.006